PURPOSE: The objective of this study was to investigate whether high levels of serum interleukin (IL)-6, C-reactive protein (CRP), and alpha1-antichymotrypsin (ACT) were associated with the loss of muscle strength or muscle mass (sarcopenia) in older persons. SUBJECTS: The study included 986 men and women of the Longitudinal Aging Study Amsterdam, with a mean age of 74.6 years (standard deviation 6.2). METHODS: Grip strength (n = 986) and appendicular muscle mass (n = 328, using dual-energy x-ray absorptiometry) were obtained in 1995 and 1996 and repeated after a 3-year follow-up. Loss of muscle strength was defined as a loss of grip strength greater than 40%, and sarcopenia was defined as a loss of muscle mass greater than 3%, approximating the lowest 15% of the study sample. RESULTS: Multiple linear and logistic regression analyses revealed that higher levels of IL-6 were associated with greater decline in muscle strength, which decreased by -3.21 kg (standard error 0.81) per standard deviation increase in log-transformed IL-6. After adjustment for confounders, including sociodemographic, health, and lifestyle factors, high IL-6 (>5 pg/mL) and high CRP (>6.1 mug/mL) were associated with a 2 to 3-fold greater risk of losing greater than 40% of muscle strength. Persons with high levels of ACT (>181% of the normal human pooled plasma) were 40% less likely to experience loss of muscle strength and tended (P = .07) to have a smaller decline in muscle mass compared with those in the lowest quartile of ACT. No consistent associations of IL-6 and CRP with sarcopenia were found. CONCLUSION: The findings of this prospective, population-based study suggest that higher levels of IL-6 and CRP increase the risk of muscle strength loss, whereas higher levels of ACT decrease the risk of muscle strength loss in older men and women.
PURPOSE: The objective of this study was to investigate whether high levels of serum interleukin (IL)-6, C-reactive protein (CRP), and alpha1-antichymotrypsin (ACT) were associated with the loss of muscle strength or muscle mass (sarcopenia) in older persons. SUBJECTS: The study included 986 men and women of the Longitudinal Aging Study Amsterdam, with a mean age of 74.6 years (standard deviation 6.2). METHODS: Grip strength (n = 986) and appendicular muscle mass (n = 328, using dual-energy x-ray absorptiometry) were obtained in 1995 and 1996 and repeated after a 3-year follow-up. Loss of muscle strength was defined as a loss of grip strength greater than 40%, and sarcopenia was defined as a loss of muscle mass greater than 3%, approximating the lowest 15% of the study sample. RESULTS: Multiple linear and logistic regression analyses revealed that higher levels of IL-6 were associated with greater decline in muscle strength, which decreased by -3.21 kg (standard error 0.81) per standard deviation increase in log-transformed IL-6. After adjustment for confounders, including sociodemographic, health, and lifestyle factors, high IL-6 (>5 pg/mL) and high CRP (>6.1 mug/mL) were associated with a 2 to 3-fold greater risk of losing greater than 40% of muscle strength. Persons with high levels of ACT (>181% of the normal human pooled plasma) were 40% less likely to experience loss of muscle strength and tended (P = .07) to have a smaller decline in muscle mass compared with those in the lowest quartile of ACT. No consistent associations of IL-6 and CRP with sarcopenia were found. CONCLUSION: The findings of this prospective, population-based study suggest that higher levels of IL-6 and CRP increase the risk of muscle strength loss, whereas higher levels of ACT decrease the risk of muscle strength loss in older men and women.
Authors: M Inzitari; E Doets; B Bartali; V Benetou; M Di Bari; M Visser; S Volpato; G Gambassi; E Topinkova; L De Groot; A Salva Journal: J Nutr Health Aging Date: 2011-08 Impact factor: 4.075
Authors: Amanda H Salanitro; Christine S Ritchie; Martha Hovater; David L Roth; Patricia Sawyer; Julie L Locher; Eric Bodner; Cynthia J Brown; Richard M Allman Journal: Arch Gerontol Geriatr Date: 2012-02-04 Impact factor: 3.250
Authors: Carlo Custodero; Stephen D Anton; Daniel P Beavers; Robert T Mankowski; Stephanie A Lee; Mary M McDermott; Roger A Fielding; Anne B Newman; Russel P Tracy; Stephen B Kritchevsky; Walter T Ambrosius; Marco Pahor; Todd M Manini Journal: Arch Gerontol Geriatr Date: 2020-05-30 Impact factor: 3.250
Authors: Michelle Shardell; Christopher D'Adamo; Dawn E Alley; Ram R Miller; Gregory E Hicks; Yuri Milaneschi; Richard D Semba; Antonio Cherubini; Stefania Bandinelli; Luigi Ferrucci Journal: J Am Geriatr Soc Date: 2012-01-27 Impact factor: 5.562
Authors: Candace K McClure; Samar R El Khoudary; Carrie A Karvonen-Gutierrez; Kelly R Ylitalo; Kristin Tomey; Trang VoPham; Barbara Sternfeld; Jane A Cauley; Siobán Harlow Journal: Exp Gerontol Date: 2013-11-07 Impact factor: 4.032
Authors: Alejandro Schcolnik-Cabrera; Alma Chávez-Blanco; Guadalupe Domínguez-Gómez; Alfonso Dueñas-González Journal: Am J Cancer Res Date: 2017-05-01 Impact factor: 6.166